Pura Vida Investments’s Innate Pharma IPHA Stock Holding History

Pura Vida Investments’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-79,896	Closed	-$364K	–	256
2021 Q4	$364K	Sell	79,896 -2,613	-3%	-$13.9K	0.01%	217
2021 Q3	$509K	Buy	+82,509	New	+$355K	0.02%	249

Other funds holding IPHA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

Pura Vida Investments's IPHA Position: Q1 2022 in Review

Pura Vida Investments sold out of Innate Pharma (IPHA) in Q1 2022, closing a stake of 79,896 shares — an estimated $364K sold.

Pura Vida Investments first reported a position in IPHA in Q3 2021 and held it in 2 quarters. The position peaked at $509K in Q3 2021. 13 funds tracked by Wall St. Rank hold IPHA as of Q1 2022.

Pura Vida Investments reported no remaining Innate Pharma position as of Q1 2022 after selling out during the quarter.
Pura Vida Investments sold 79,896 Innate Pharma shares in Q1 2022, an estimated $364K.
Pura Vida Investments first reported a position in Innate Pharma in Q3 2021 and held it in 2 quarters.
Pura Vida Investments's Innate Pharma position peaked at $509K in Q3 2021.
13 funds tracked by Wall St. Rank held Innate Pharma as of Q1 2022.

Based on Pura Vida Investments's 13F filing for Q1 2022, filed 16 May 2022.